Beyond the Injection: Why GLP-1 Drugs Alone Cannot Fix Obesity

The arrival of glucagon-like peptide-1 receptor agonists, the class of drugs popularly known as GLP-1 therapies, has transformed the public conversation about obesity. Medications such as semaglutide and tirzepatide have demonstrated weight reductions that earlier pharmacological options never approached, and demand has surged to the point where supply shortages have become recurring news stories in their own right. Yet a new Perspective published in JAMA by researchers including corresponding author Francesca Celletti of the Department of Nutrition and Food Safety at the World Health Organization argues that the enthusiasm for these drugs risks obscuring a more fundamental truth: obesity is a chronic, relapsing, multifactorial disease that no single injection can resolve on its own.

The Perspective, published in the JAMA Network on 1 October 2026, urges clinicians and health systems to build multimodal management of obesity that extends well beyond pharmacological treatment. According to the authors, effective care must integrate screening, early management, and intensive behavioral therapy across the entire life course. The argument is not a rejection of GLP-1 therapies, which the authors implicitly recognize as a powerful new tool, but a warning against treating them as a complete solution. Obesity, they contend, requires the same kind of comprehensive, long-term clinical architecture that other chronic diseases have demanded for decades.

The scientific rationale for this position rests on the biology of obesity itself. Body fat mass is regulated by a network of hormonal, neural, and behavioral feedback loops centered on the hypothalamus, the gut, adipose tissue, and the reward circuits of the brain. GLP-1 receptor agonists intervene at one crucial node of this network: they mimic an incretin hormone released after meals, slowing gastric emptying, enhancing satiety, and reducing appetite through both hypothalamic and higher-order neural pathways. Newer agents add glucose-dependent insulinotropic polypeptide activity, further improving metabolic outcomes. The results in randomized trials have been striking, with double-digit percentage losses of body weight now achievable pharmacologically for the first time.

But the same biology explains why medication alone is structurally insufficient. Obesity is characterized by adaptations in energy homeostasis that defend body fat stores. When caloric intake falls, whether through diet, surgery, or drugs, compensatory mechanisms increase hunger, reduce satiation, and lower resting energy expenditure. Trials of GLP-1 therapies have shown that discontinuation is typically followed by substantial weight regain, a pattern consistent with the rebound observed after intensive lifestyle interventions and bariatric surgery. The disease process persists beneath the treatment effect, which is why the Perspective frames pharmacotherapy as one component of a durable management strategy rather than a cure.

This is where the multimodal model becomes central. The authors call for systematic screening so that obesity and its early metabolic disturbances are identified before they progress to established comorbidities such as type 2 diabetes, cardiovascular disease, nonalcoholic fatty liver disease, obstructive sleep apnea, and several obesity-associated cancers. Early management, in their framing, means intervening at the stage when lifestyle change and modest pharmacological support can alter trajectory most effectively, rather than waiting until advanced disease leaves fewer options. Screening also carries an equity dimension, because obesity prevalence and access to care vary sharply across socioeconomic groups and regions, and late diagnosis tends to concentrate in populations with the fewest resources.

Intensive behavioral therapy forms the third pillar. Decades of research, including the landmark Diabetes Prevention Program, have established that structured programs combining dietary change, physical activity, and behavior modification can produce meaningful weight loss and reduce progression to type 2 diabetes, even before modern drugs existed. The Perspective argues that these interventions should not be displaced by pharmacotherapy but combined with it. Behavioral support addresses the skills, environment, and psychological factors that determine whether initial weight loss is maintained, and it remains the component of care that patients continue to control after any prescription ends. In a health system organized around multimodal care, a patient beginning a GLP-1 medication would simultaneously receive nutritional counseling, physical activity guidance, and structured follow-up designed to outlast the treatment period.

The life-course emphasis of the Perspective adds a further layer of urgency. Obesity develops through interactions of genetics, early-life nutrition, environment, and behavior, and its consequences accumulate across decades. Adiposity established in childhood and adolescence tracks strongly into adulthood and raises the lifetime burden of cardiometabolic disease. At the other end of the age spectrum, older adults face the dual challenge of excess fat mass and loss of lean muscle, making weight management strategies that preserve muscle and bone particularly important. A therapy-centered model that ignores these developmental windows, the authors suggest, will systematically miss the points of maximum leverage.

The comorbidity dimension is equally consequential. Obesity rarely travels alone; it clusters with hypertension, dyslipidemia, insulin resistance, chronic kidney disease, and mental health conditions including depression, and it multiplies the clinical complexity of each. Interestingly, some GLP-1 and related agents have shown cardiovascular and renal benefits in dedicated outcome trials, suggesting that the pharmacological era may deliver dividends beyond weight itself. Even so, the Perspective’s central claim stands: managing the comorbidities of obesity requires coordinated clinical attention to each condition, integrated screening protocols, and care pathways that treat the patient as a whole rather than a prescription target. Multimodal care, in this vision, is as much about health-system design as about individual treatment choices.

The timing of the argument reflects a real-world inflection point. Health systems are currently absorbing the consequences of explosive GLP-1 demand: shortages, questions about lifelong therapy costs, insurance coverage debates, and a growing population of patients who begin these drugs without any accompanying behavioral or nutritional support. Clinical guidelines from major professional societies already recommend that pharmacotherapy be combined with lifestyle intervention, but implementation has lagged, driven by cost, workforce limitations, and fragmented reimbursement. The Perspective effectively functions as a policy signal, urging that the infrastructure of obesity care, from primary care screening to structured behavioral programs, be built in parallel with drug access rather than as an afterthought.

What emerges from the JAMA Perspective is a pragmatic synthesis rather than a rejection of the pharmacological revolution. GLP-1 therapies have removed one of the most discouraging barriers in obesity medicine, the limited efficacy of available drugs, and they deserve a central place in treatment. But the disease they treat is chronic, adaptive, and woven into behavior and environment across a lifetime. The authors’ prescription is correspondingly broad: screen early, intervene early, deliver intensive behavioral therapy, combine these elements with medication where appropriate, and sustain care across the life course. If health systems follow that blueprint, the GLP-1 era may be remembered not as the moment obesity was medicated, but as the moment its comprehensive management finally became possible.

Subject of Research: Multimodal clinical management of obesity and its comorbidities in the era of GLP-1 receptor agonist therapies

Article Title: Building effective multimodal care for obesity and comorbidities in the GLP-1 therapy era

Article References: Building effective multimodal care for obesity and comorbidities in the GLP-1 therapy era. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: obesity, GLP-1 receptor agonists, multimodal care, behavioral therapy, comorbidities, screening, JAMA, World Health Organization, chronic disease, weight regain, life course, health systems